Related references
Note: Only part of the references are listed.Interaction Between Everolimus and Tacrolimus in Renal Transplant Recipients: A Pharmacokinetic Controlled Trial
Julio Pascual et al.
TRANSPLANTATION (2010)
Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial
Gregg W. Stone et al.
CIRCULATION (2009)
Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
Stephane Oudard et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Xience V™ everolimus-eluting coronary stent
Neville Kukreja et al.
EXPERT REVIEW OF MEDICAL DEVICES (2009)
The Everolimus-Eluting Stent in Real-World Patients 6-Month Follow-Up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) Registry
Yoshinobu Onuma et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function
Paolo De Simone et al.
TRANSPLANT INTERNATIONAL (2009)
Incidence of Delayed Graft Function and Wound Healing Complications After Deceased-Donor Kidney Transplantation Is not Affected by De Novo Everolimus
Laetitia Albano et al.
TRANSPLANTATION (2009)
Everolimus With Reduced Cyclosporine Versus MMF With Standard Cyclosporine in De Novo Heart Transplant Recipients
Hans B. Lehmkuhl et al.
TRANSPLANTATION (2009)
Drug-eluting stents: a comprehensive appraisal
Mehmood Butt et al.
FUTURE CARDIOLOGY (2009)
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease - A randomized trial
Gregg W. Stone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Comparison between a liquid chromatography-tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantations
Eric Dailly et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)
Imad Sheiban et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2008)
Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms
Judith Gomez-Camarero et al.
TRANSPLANTATION (2007)
Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A
Lars Pape et al.
PEDIATRIC TRANSPLANTATION (2007)
Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: A 24-month analysis
Mario Vigano et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2007)
Everolimus drug interactions: Application of a classification system for clinical decision making
John M. Kovarik et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2006)
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12-and 36-month results
Gary Levy et al.
LIVER TRANSPLANTATION (2006)
Everolimus versus azathioprine in maintenance lung transplant recipients: An international, randomized, double-blind clinical trial
GI Snell et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Everolimus - A review of its use in renal and cardiac transplantation
C Dunn et al.
DRUGS (2006)
Growing roles for the mTOR pathway
DD Sarbassov et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients
S Vítko et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Chronic renal allograft dysfunction
JR Chapman et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Everolimus versus mycophenolate mofetil in the prevention of rejection in de Novo renal transplant recipients: A 3-year randomized, multicenter, phase III study
MI Lorber et al.
TRANSPLANTATION (2005)
Blood concentrations of everolimus are markedly increased by ketoconazole
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population - One-year results of the Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registry
ATL Ong et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data
MI Lorber et al.
CLINICAL TRANSPLANTATION (2005)
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies
S Vitko et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the real world -: The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry
PA Lemos et al.
CIRCULATION (2004)
Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling
RC Starling et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study
B Nashan et al.
TRANSPLANTATION (2004)
Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients
K Budde et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Clinical pharmacokinetics of everolimus
GI Kirchner et al.
CLINICAL PHARMACOKINETICS (2004)
Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients
HJ Eisen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Everolimus in pediatric de novo renal transplant patients
PF Hoyer et al.
TRANSPLANTATION (2003)
Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients
GI Kirchner et al.
TRANSPLANTATION PROCEEDINGS (2002)
Effect of rifampin on apparent clearance of everolimus
JM Kovarik et al.
ANNALS OF PHARMACOTHERAPY (2002)
Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients
R Van Damme-Lombaerts et al.
PEDIATRIC TRANSPLANTATION (2002)
Short course induction immunosuppression with thymoglobulin for renal transplant recipients
IA Agha et al.
TRANSPLANTATION (2002)
Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Effect of food on everolimus absorption: Quantification in healthy subjects and a confirmatory screening in patients with renal transplants
JM Kovarik et al.
PHARMACOTHERAPY (2002)
Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: A clinically relevant pharmacokinetic interaction
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Pharamacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients
GA Levy et al.
TRANSPLANTATION (2001)
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine
JM Kovarik et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Clinical pharmacokinetics of sirolimus
K Mahalati et al.
CLINICAL PHARMACOKINETICS (2001)
Share Paper
